
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet demonstrated robust financial performance with global Omnipod sales increasing by 26% year-over-year on an underlying basis in Q4 2024, reaching $586 million. The company attained significant milestones, with over 500,000 active global customers and steady year-over-year utilization and retention rates, indicating a strong momentum in Omnipod adoption across various markets. Additionally, Insulet's 2024 sales totaled $2.07 billion, marking a 22% increase year-over-year, along with an EPS of $3.24 that surpassed consensus estimates, further reinforcing a positive outlook for the company's growth trajectory.
Bears say
The financial analysis of Insulet reveals concerning trends, including a decline in operating margins by 240 basis points year-over-year, raising questions about operational efficiency. Furthermore, the company faces significant challenges with a projected drop of 45-55% in Drug Delivery revenues, alongside weak guidance for overall sales growth, which has fallen slightly short of expectations. These issues, compounded by reliance on third-party distributors and potential competitive pressures, create increased risks to revenue stability and long-term growth prospects.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares